You need to load/activate the cURL extension (
Drug nameAbarelix
DescriptionSynthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
DrugBankPrimary Accession Number: DB00106
DINNot available
TypeApproved, Biotech, Investigational, Withdrawn
IndicationFor palliative treatment of advanced prostate cancer.
Mechanism of ActionAbarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.
AbsorptionFollowing IM administration of 100 mg, abarelix is absorbed slowly with a mean peak concentration of 43.4 ng/mL observed approximately 3 days after the injection.
ToxicityThe maximum tolerated dose of abarelix has not been determined. The maximum dose used in clinical studies was 150 mg. There have been no reports of accidental overdose with abarelix.
Protein Binding96-99%